.webp&w=384&q=75){kind=logo}
Loading, please wait...
Loading, please wait...
Prostate cancer remains a significant global health burden, especially as it progresses to advanced stages. Most patients initially respond well to primary treatment. However, many eventually encounter prostate cancer ADT resistance. This state, known as castration-resistant prostate cancer (CRPC), involves complex molecular adaptations. These changes allow tumors to survive without high androgen levels. Consequently, clinicians must understand these drivers to improve patient survival and long-term outcomes.
Resistance often stems from androgen receptor (AR) modifications. These include receptor amplification and point mutations. Furthermore, the development of constitutively active splice variants, such as AR-V7, plays a major role. Alternative signaling pathways also bypass standard treatments. Specifically, the PI3K/AKT/mTOR and JAK/STAT pathways drive tumor cell survival. Recent studies even highlight proteins like BCL2 as key factors in therapy evasion.
Overcoming resistance requires identifying new therapeutic targets. Clinicians are currently exploring next-generation AR signaling inhibitors and chemotherapy combinations. Moreover, radioligand therapies like 177Lu-PSMA-617 show significant promise for patients. PARP inhibitors also offer hope for individuals with specific DNA repair mutations. Additionally, researchers are investigating BCL2 inhibitors to sensitize resistant cells to existing medications.
Biomarkers are essential for the future of personalized medicine. Emerging options like circulating tumor DNA (ctDNA) and PTEN status provide real-time data. While many of these remain insufficiently validated, they could soon guide clinical decisions. Therefore, ongoing research into these invasive markers is vital for refining treatment protocols.
Resistance primarily involves androgen receptor amplification, mutations, and the expression of splice variants like AR-V7. Additionally, the activation of alternative pathways such as PI3K/AKT/mTOR contributes to therapy failure.
Most emerging biomarkers, including ctDNA and certain protein markers, are still undergoing clinical validation. However, they show great potential for real-time monitoring of disease progression and resistance.
Disclaimer: This content is for informational and educational purposes only. It does not constitute medical advice or a professional recommendation. Always consult with a qualified healthcare provider for personal health concerns. Refer to the latest local and national guidelines for clinical practice.
References
Bensalim I et al. Mechanisms of resistance to androgen deprivation therapy in prostate cancer. Mol Aspects Med. 2026 Jun 18. doi: undefined. PMID: 42314224.
Watson PA, et al. Emerging mechanisms of resistance to androgen receptor-directed therapy in prostate cancer. Nat Rev Cancer. 2015;15(12):701-711.
Chandrasekar T, et al. Mechanisms of resistance in castration-resistant prostate cancer. Transl Androl Urol. 2015;4(3):365-380.
Read summarized clinical updates, watch expert medical content, and earn CME certifications right from your smartphone.
Open your smartphone camera to scan and install.
This review outlines the molecular drivers of prostate cancer ADT resistance, including AR mutations and alternative signaling. It also evaluates emerging biomarkers like ctDNA and therapeutic strategies like radioligand therapy to improve clinical outcomes in castration-resistant states.
last month
Researchers at Kyushu University have uncovered a novel compound, lipoic acid trisulfide (LASSS), that enhances hepatocyte growth factor (HGF) signaling and protects against nitration-induced protein dysfunction, presenting a potential breakthrough for age-related muscle atrophy and sarcopenia.
Yesterday
A study identifies a critical hypospadias gene-environment interaction. Research shows that the risk gene DNAH8 and DEHP exposure combine to disrupt steroidogenesis and mesenchymal progenitor cell differentiation, significantly increasing the risk of severe urethral malformations in male fetuses.
5 days back
A pre-clinical study reveals that elevated serum pro-N-cadherin levels correlate strongly with severe cardiac fibrosis and diastolic dysfunction following radiation exposure, promising a potential early biomarker for radiation-related heart disease.
3 days back
Discover how biophysical forces shape tissue formation and regeneration. This review explores mechanotransduction in tissue development, from molecular sensors like integrins to tissue-scale flows, highlighting critical implications for regenerative medicine and functional organoid engineering.
Last week
A groundbreaking study utilizes single-cell RNA sequencing to map the tumor microenvironment of ovarian steroid cell tumors-not otherwise specified (SCT-NOS), identifying key steroidogenic subtypes and immune cell distributions that drive hyperandrogenism and tumor progression.
Last week
